News & Promotions

Provide total solutions for Life Science applications together with global partners. We are constantly striving to be more
connected, forward-looking and customer-focused to deliver best results.

News & Promotions

News

[immusmol] Plasma L-Arginine levels assessed by ELISA predict response of cancer patients to immune checkpoint blockers

관리자 2022.09.19 11:22 조회 14 추천 0
bric-banner-new800.png




New-logo.PNG



Plasma L-Arginine levels assessed by ELISA predict response of cancer patients 
to immune checkpoint blockers
New highlight in Annals of Oncology!


In the era of immuno-oncology, identification of reliable predictive biomarkers - that can help for a better selection of cancer patients who might respond to Immune Checkpoint Blockers (ICB) - remains crucial. Expression of PD-L1 on cancer cells, high micro satellite instability, and tumor mutational burden are, to date, the only predictors of ICB response while still being imperfect (1). Even though tumor tissue profiling is key for biomarker discovery, insights from the periphery are needed in order to allow an easy-to-implement clinical practice.

Immunometabolism is known to play a key role in shaping the immune response. Amino Acid degradation by tumor and/or suppressive immune cells has been shown to limit anti-tumor immune response (2, 3). In a recent study - supervised by Antoine Italiano and conducted in collaboration between teams from Explicyte (Bordeaux, France), Institut Bergonié (Bordeaux, France), and Institut Gustave Roussy (Villejuif, France), and published in Annals of Oncology (4) - plasmatic level of L-Arginine (Arg) has been found to be associated with clinical outcome of advanced cancer patients treated with ICB. Using an ELISA approach for Arg quantification (#IS-I-0400R) applied on two independent cohorts, Peyraud et al. demonstrated that low plasmatic level of Arg was associated with a worse clinical outcome. 

As a new product on the market, our novel ELISA kit for Arg quantification (#IS-I-0400R) requires as little as 20µL plasma sample volume and therefore offers a valuable and easy approach to predicting sensitivity of patients to ICB before treatment onset. 



220919-1.PNG

220919-2.PNG


partner-new.png


(주)엘바이오시스템은 immusmol의 한국공식대리점입니다.
제품의 주문 및 관련정보가 필요하시면 이메일로 문의해 주세요.